Three-dimensional cell culture: Future scope in cancer vaccine development

IF 6.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Discovery Today Pub Date : 2024-07-25 DOI:10.1016/j.drudis.2024.104114
Mahfoozur Rahman , Ankit Sahoo , Waleed H. Almalki , Salem Salman Almujri , Alhussain Aodah , Abdulrahman A. Alnofei , Abdulrahman Alhamyani
{"title":"Three-dimensional cell culture: Future scope in cancer vaccine development","authors":"Mahfoozur Rahman ,&nbsp;Ankit Sahoo ,&nbsp;Waleed H. Almalki ,&nbsp;Salem Salman Almujri ,&nbsp;Alhussain Aodah ,&nbsp;Abdulrahman A. Alnofei ,&nbsp;Abdulrahman Alhamyani","doi":"10.1016/j.drudis.2024.104114","DOIUrl":null,"url":null,"abstract":"<div><p>Three-dimensional (3D) cell culture techniques, which are superior to 2D methods in viability and functionality, are being used to develop innovative cancer vaccines. Tumor spheroids, which are structurally and functionally similar to actual tumors, can be developed using 3D cell culture. These spheroid vaccines have shown superior antitumor immune responses to 2D cell-based vaccines. Dendritic cell vaccines can also be produced more efficiently using 3D cell culture. Personalized cancer vaccines are being developed using 3D cell culture, providing substantial benefits over 2D methods. The more natural conditions of 3D cell culture might promote the expression of tumor antigens not expressed in 2D culture, potentially allowing for more targeted vaccines by co-culturing tumor cells with other cell types. Advanced cancer vaccines using 3D cell cultures are expected soon.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104114"},"PeriodicalIF":6.5000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644624002393","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Three-dimensional (3D) cell culture techniques, which are superior to 2D methods in viability and functionality, are being used to develop innovative cancer vaccines. Tumor spheroids, which are structurally and functionally similar to actual tumors, can be developed using 3D cell culture. These spheroid vaccines have shown superior antitumor immune responses to 2D cell-based vaccines. Dendritic cell vaccines can also be produced more efficiently using 3D cell culture. Personalized cancer vaccines are being developed using 3D cell culture, providing substantial benefits over 2D methods. The more natural conditions of 3D cell culture might promote the expression of tumor antigens not expressed in 2D culture, potentially allowing for more targeted vaccines by co-culturing tumor cells with other cell types. Advanced cancer vaccines using 3D cell cultures are expected soon.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三维细胞培养:癌症疫苗开发的未来前景
三维(3D)细胞培养技术在存活率和功能方面优于二维方法,目前正被用于开发创新型癌症疫苗。利用三维细胞培养技术可以开发出在结构和功能上与实际肿瘤相似的肿瘤球体。这些球形疫苗的抗肿瘤免疫反应优于二维细胞疫苗。树突状细胞疫苗也可以利用三维细胞培养技术更高效地生产。目前正在利用三维细胞培养技术开发个性化癌症疫苗,与二维方法相比,这种方法具有很大的优势。三维细胞培养更自然的条件可能会促进二维培养中未表达的肿瘤抗原的表达,从而有可能通过将肿瘤细胞与其他细胞类型共培养,生产出更有针对性的疫苗。使用三维细胞培养的先进癌症疫苗有望很快问世。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discovery Today
Drug Discovery Today 医学-药学
CiteScore
14.80
自引率
2.70%
发文量
293
审稿时长
6 months
期刊介绍: Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
期刊最新文献
Efficacy and challenges involving combination therapies in CLL. Strategic partnerships for AI-driven drug discovery: The role of relational dynamics. Antibody-drug conjugates: prospects for the next generation. Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024. Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1